1. Optimal strategy for antiplatelet therapy after endovascular revascularization in patients with lower extremity artery disease
- Author
-
G S Kim, J K Seo, B G Kim, Y S Byun, and B O Kim
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Background The duration of antiplatelet therapy after endovascular revascularization in patients with lower extremity artery disease (LEAD) has not been well established. This study aimed to evaluate the clinical outcome according to the duration of dual antiplatelet therapy (DAPT) in real practice. Methods From April 2009 to June 2019, 376 patients with LEAD underwent successful endovascular revascularization. After the procedure, the received single antiplatelet therapy (SAPT) or DAPT of various durations were classified into two groups (SAPT or DAPT Results Over the 40-month follow-up period, MACE occurred less frequently in the DAPT ≥6 months group than that in the SAPT or DAPT Conclusions In patients with LEAD, DAPT for ≥6 months after endovascular revascularization was associated with a lower incidence of MACE. Funding Acknowledgement Type of funding sources: Public Institution(s). Main funding source(s): National Research Foundation of Korea (NRF) grant funded by the government of Korea (MSIT) (No. 2019R1G1A1100442).
- Published
- 2022